COPD Foundation announces new Bronchiectasis and NTM Care Center Network
MIAMI, (February 26, 2024) – Bronchiectasis and NTM 360, a division of the COPD Foundation, has announced the launch of the Bronchiectasis and NTM Care Center Network (CCN), a groundbreaking initiative that will facilitate access to specialized care and support for hundreds of thousands of individuals with bronchiectasis and nontuberculous mycobacterial (NTM) lung disease.
This innovative network will be implemented at 150 medical centers in diverse geographical locations nationwide over the next three years with support from Founding Sponsor Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The aim for the centers is to provide accurate, prompt diagnosis and outstanding standardized medical care, resources, and education.
«Our goals to improve care and quality of life, advance research towards a cure, and build widespread awareness can only be attained through bold vision and support from companies like Insmed,» said Jean Wright, M.D., MBA, CEO of the COPD Foundation. «As the prevalence of these diseases and the economic burden grow, early detection and education efforts are more critical than ever. This collaboration, which also includes NTM Info & Research and a steering committee of world-renowned experts and patient representation, will transform the landscape of care for individuals with bronchiectasis and NTM lung disease, providing them with the care and resources they need to thrive.»
Goals of the CCN include:
- Accelerating the time to diagnosis and delivering specialized, comprehensive, high-quality care.
- Educating health care teams about bronchiectasis and NTM lung disease and the care required to achieve and maintain the best possible outcomes.
- Supporting research and clinical trials and the development of real-world evidence.
- Delivering patient-centered education to improve long-term disease management.
- Increasing disease awareness as well as patient education and engagement.
«Having a meaningful impact on the patient community is what drives us at Insmed,» said Will Lewis, Chair and Chief Executive Officer of Insmed. «The Bronchiectasis & NTM Care Center Network brings together the COPD Foundation, NTM Info & Research, and a steering committee of the top experts in the world with the goal of transforming care delivery for patients. We could not be prouder to serve as the Founding Sponsor and look forward to the many ways in which the CCN will benefit patients and their families for years to come.»
In addition to the CCN, Bronchiectasis and NTM 360 is developing a patient-reported registry of individuals with bronchiectasis and NTM lung disease that will provide a greater wealth of data on patient experience and journey, and will impact the direction of education and research.
For more information, clic here, visit Bronchiectasis and NTM Care Center Network or bronchiectasisandntm360.org.
Puedes leer el artículo completo aquí: https://www.copdfoundation.org/About-Us/Press-Room/Press-Releases/Article/1931/COPD-Foundation-announces-new-Bronchiectasis-and-NTM-Care-Center-Network-with-s.aspx
Noticias relacionadas
Relationship between Respiratory Microbiome and Systemic Inflammatory Markers in COPD: A Pilot Study
This study explores how changes in the respiratory microbiome relate to systemic inflammation in COPD patients. It highlights correlations between bacterial abundance, eosinophilic markers, and airflow limitation severity.
Telomere length in patients with bronchiectasis
This study investigates telomere length (TL) in bronchiectasis patients, comparing them to COPD patients and healthy controls. Findings show no significant TL reduction in bronchiectasis compared to controls, but a trend towards shorter TL in idiopathic cases. Further research is needed to understand TL’s role in bronchiectasis.
Pathophysiology and genomics of bronchiectasis
Explore the complex pathophysiology of bronchiectasis, including airway infection, chronic inflammation, and mucociliary dysfunction. Learn how genomic approaches, proteomics, and epigenomics offer new insights into disease endotypes and patient stratification for improved therapies. Discover the role of trained innate immunity in complementing current models.
Artículos
COPD
- 759578·Alberto Papi et Al.-Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
Imagen realizada con los logos oficiales de COPD Foundation e imágenes de Canva Pro.